This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. **(Original)** A method for eliminating or reducing normal but undesired tissue in a patient which comprises administering a controlled release formulation to the patient by injection at a local area containing the undesired tissue such that the undesired tissue in the local area is eliminated or reduced, said formulation comprising a substance which eliminates or prevents formation of the cells of the undesired tissue, said substance being provided in a controlled release carrier.

2. **(Original)** The method of claim 1 where the undesired tissue is fat tissue.

3. **(Previously presented)** The method of claim 2 where the substance which eliminates or prevents formation of cells of the fat tissue is TNF-α.

4. **(Original)** The method of claim 2 where the substance which eliminates or prevents formation of cells of the fat tissue is a cytokine regulatory agent; a protein affecting fat metabolism; leptin; orexin; an antisense RNA molecule which knocks out the specific activity of a protein needed for fat cell maintenance; a DNA, either in the form of plasmid or virus, which induces the expression of apoptosis-inducing factors; a drug that kills fat cells; methotrexate; bromo-deoxyuridine; actinomycin D; nocodazole; brefeldin A; a peptide, having functionality which kills fat cells; prolactin; a beta-adrenergic stimulator; or, an alpha-2 adrenergic inhibitor.

5. **(Original)** The method of claim 1 where the controlled release carrier is comprised of a poly(lactide-co-glycolide) material.

6. **(Original)** The method of claim 2 where the controlled release carrier is comprised of a poly(lactide-co-glycolide) material.

7. **(Original)** The method of claim 1 where the controlled release formulation is injected multiple times distributed in the local area of the undesired tissue.

8. **(Original)** The method of claim 2 where the controlled release formulation is injected multiple times distributed in the local area of the undesired fat tissue.

9. **(Original)** The method of claim 1 where release of the substance which eliminates or prevents formation of cells of the undesired tissue is effected over at least 3 days by the controlled release carrier.

10. **(Original)** The method of claim 2 where release of the substance which eliminates or prevents formation of cells of the undesired fat tissue is effected over at least 3 days by the controlled release carrier.

11. **(Original)** The method of claim 9 where the substance which eliminates or prevents formation of cells of the undesired tissue is released in a substantially equal amount for each of the days of release.

12. **(Original)** The method of claim 10 where the substance which eliminates or prevents formation of cells of the undesired tissue is released in a substantially equal amount for each of the days of release.

13. **(Original)** The method of claim 1 where the undesired tissue is pathologic hyperplasia, benign tumor, neointimal thickened vasculature, mole or hair tissue.

14. **(Original)** The method of claim 3 where the controlled release carrier is comprised of a poly(lactide-co-glycolide) material.

15. **(Original)** The method of claim 14 where the TNF-α is provided in poly(lactide-co-glycolide) microspheres in an amount of from 0.1 to 20% by weight.

16. **(Original)** The method of claim 14 where the controlled release carrier provides

in vivo release of the TNF-α for a period of 7 to 60 days.

17. **(Original)** The method of claim 1 where the controlled release carrier is comprised of a poly(lactide), poly(glycolide), poly(lactic acid), poly(glycolic acid), polyanhydride, polyorthoester, polyetherester, polycaprolactone, polyesteramide, polycarbonate, polycyanoacrylate, polyurethane, polyacrylate, blends or copolymer of the above polymers, a hydrogel, an alginate or modified alginate, or a polyethylene glycol group-containing macromolecule for conjugation of the active substance.

18. – 23. **(Canceled)**

24. **(Original)** The method claim 1 wherein the formulation comprises two or more substances in the controlled release carrier having a combined action of eliminating or preventing formation of the cells of the undesired tissue.

25. **(Original)** The method of claim 24 wherein at least one of the substances is released from the controlled release carrier later in time than another of the substances.

26. **(Original)** The method of claim 25 wherein a first substance released is an anti-angiogenic compound which hinders the blood supply to the unwanted tissue and a second substance is released later in time which induces apoptosis in the unwanted tissue.

27. **(Original)** The method of claim 25 for removing unwanted bone tissue wherein a first substance is released which demineralizes the bone tissue and a second substance is released later in time which kills cells of the bone tissue.

28. – 31. **(Canceled)**

32. **(New)** The method of claim 1, wherein the controlled release formulation is injected directly into tissue to be eliminated or reduced by subcutaneous or omental injection.